A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.
Camille N. Abboud(Washington University in St. Louis), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Olga Frankfurt, Alicia Wong(Broad Institute), Rick Mamelok(Cellerant Therapeutics (United States)), Lois Kellerman(Cellerant Therapeutics (United States)), Brown Janice(Stanford University), James M. Foran(Memorial Sloan Kettering Cancer Center), Gary J. Schiller(Fred Hutch Cancer Center), Saar Gill(Parker Institute for Cancer Immunotherapy), John M. Pagel(University of Washington), Charalambos Andreadis(University of California, San Francisco), Celalettin Üstün(Rush University Medical Center), Pinkal Desai(NewYork–Presbyterian Hospital), John Lister(Allegheny Health Network), Rodney Van Syoc(Cellerant Therapeutics (United States)), Melham Solh(Northside Hospital), Luke P. Akard(Franciscan Health Indianapolis), Jack W. Hsu(University of Florida Health), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist)
Cited by 3
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k